Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000179
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-10-29
Brief Title:
Agitation in Alzheimers Disease
Sponsor:
National Institute on Aging NIA
Organization:
National Institute on Aging NIA
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2005-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Agitation affects 70 to 90 percent of patients with AD Signs of agitation include verbal and physical aggressiveness irritability wandering and restlessness These behaviors often make caring for patients at home very difficult Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients Behavior management a non drug approach has been effective in reducing signs of agitation Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment The Alzheimers Disease Cooperative Study with funding from the National Institute on Aging is conducting an agitation treatment program at 21 sites in 16 States This study will assess which of the above treatments is most effective
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 3U01AG010483-08S2 | NIH | None | httpsreporternihgovquickSearch3U01AG010483-08S2 |